Defibrillator - Market Insights, Competitive Landscape, and Market Forecast - 2034

Defibrillator Market Summary

Overview:

• The Defibrillator market is estimated at USD 13.20 billion in 2025 and is projected to reach USD 24.90 billion by 2034. Growth is anchored in the rising burden of cardiovascular disease and sudden cardiac arrest, expanding public-access defibrillation, and continuous innovation in implantable and wearable defibrillation technologies.
• The global Defibrillator market is growing at a CAGR of 7.3% during the forecast period from 2026 to 2034.
• By product type, the implantable cardioverter defibrillator (ICD) segment dominated the Defibrillator market with a 68% share in 2025.
• By end-user, the hospitals segment dominated the Defibrillator market with a 69% share in 2025.
• North America dominated the global Defibrillator market revenue with a 45% share in 2025, representing the highest regional market share globally.

A defibrillator is a life-saving medical device that delivers a controlled electrical shock to the heart to terminate life-threatening arrhythmias, principally ventricular fibrillation and pulseless ventricular tachycardia, and restore a normal rhythm. Defibrillators fall into two broad families. Implantable cardioverter defibrillators (ICDs) are surgically placed devices that continuously monitor heart rhythm and automatically deliver anti-tachycardia pacing or shocks, and they include single-chamber ICDs, dual-chamber ICDs, cardiac resynchronization therapy defibrillators (CRT-D), and subcutaneous ICDs (S-ICD). External defibrillators are used outside the body by clinicians, first responders, or lay bystanders, and include semi-automated devices, automated external defibrillators (AEDs), and wearable cardioverter defibrillators. The market is organized by product type across implantable and external defibrillators; by end-user across hospitals, ambulatory surgical centers, homecare settings, and others; and by geography across North America, Europe, Asia-Pacific, and the Rest of the World. Driven by the global burden of cardiovascular disease, the expansion of public-access defibrillation programs, and innovation in extravascular, leadless-compatible, connected, and wearable systems, defibrillators have become essential infrastructure in the prevention and treatment of sudden cardiac death.

Defibrillator Market Key Growth Drivers

• The rising burden of cardiovascular disease and sudden cardiac arrest is driving demand, with the World Health Organization estimating that cardiovascular diseases caused about 19.8 million deaths worldwide in 2022 and more than 350,000 out-of-hospital cardiac arrests occurring in the United States each year.
• Population aging and the growing prevalence of heart failure and ventricular arrhythmias are expanding the pool of patients eligible for ICD and CRT-D therapy.
• Public-access defibrillation programs, AED mandates in schools, workplaces, and transport hubs, and heightened public awareness are expanding the installed base of automated external defibrillators, with survival chances falling by roughly 10% for every minute defibrillation is delayed.
• Technology innovation, including extravascular ICDs, subcutaneous and modular leadless-compatible systems, conduction-system-pacing-capable defibrillators, connected AEDs, and AI-enabled wearable defibrillators, is broadening clinical indications and patient acceptance.
• A steady cadence of regulatory approvals and product launches, such as the 2026 FDA approval of BIOTRONIK's Acticor Sky and Rivacor Sky systems and the 2025 FDA premarket approval of ZOLL's Zenix monitor/defibrillator, is refreshing the installed base and supporting replacement demand.
• The shift of care toward ambulatory and home settings, supported by wearable defibrillators, home AEDs, and remote monitoring, is opening new demand channels beyond the hospital.
• The convergence of disease burden, public-access expansion, innovation, and care-setting shift is expected to sustain steady, high-single-digit growth in the market through 2034.

Key Companies in Defibrillator Market

The competitive landscape is led by the following active manufacturers:

• Abbott
• Medtronic
• Boston Scientific Corporation
• Stryker
• Koninklijke Philips N.V.
• ZOLL Medical Corporation
• MicroPort Scientific Corporation
• LivaNova PLC
• Biotronik, Inc.
• Nihon Kohden Corporation

Factors Contributing to the Growth of the Defibrillator Market

Market Drivers

Rising Burden of Cardiovascular Disease and Sudden Cardiac Arrest

The most powerful driver of the Defibrillator market is the large and growing burden of cardiovascular disease. The World Health Organization estimates that cardiovascular diseases caused about 19.8 million deaths worldwide in 2022, making them the leading cause of death globally, while in the United States more than 350,000 cardiac arrests occur outside the hospital every year and survival to hospital discharge remains around 10%. Because ventricular fibrillation is reversible only through rapid defibrillation, and survival chances fall by roughly 10% for every minute of delay, defibrillators are among the most time-critical and highest-value interventions in cardiology. Implantable devices protect patients who have survived a prior arrest or carry a high risk of ventricular arrhythmia, while external devices serve the far larger population at risk of an unexpected event. As ischemic heart disease, cardiomyopathy, and arrhythmia prevalence rise, demand for both implantable and external defibrillators expands in step, anchoring market growth through 2034.

Population Aging and Growth in Heart Failure

Demographic change is steadily enlarging the addressable patient pool. Older adults carry the highest prevalence of heart failure, prior myocardial infarction, and ventricular arrhythmia, which are the principal clinical indications for ICD and CRT-D therapy under major cardiology guidelines. Improved survival after myocardial infarction and better long-term heart-failure management are also creating a larger cohort of patients who live long enough to qualify for device therapy. Combination CRT-D devices, which pair resynchronization with defibrillation for patients with heart failure and conduction delay, are benefiting directly from this trend. Rising life expectancy in Japan, Europe, China, and North America, together with greater referral and screening of at-risk patients, supports sustained procedure volumes and device replacement cycles across the forecast period.

Market Restraints

Despite strong momentum, the Defibrillator market faces material constraints. The high cost of implantable devices, implant procedures, and follow-up care, together with uneven reimbursement across countries, limits adoption in cost-sensitive and emerging markets. Implant-related complications, including lead failure, infection, vascular injury, and inappropriate shocks, create clinical risk, drive revisions, and can discourage patients and referring physicians. Stringent regulatory requirements, including FDA premarket approval and EU MDR certification, lengthen development timelines and raise costs, and the industry has seen recalls tied to issues such as power-supply failures and unexpected device shutdowns. Evolving clinical evidence, such as debate over the benefit of primary-prevention ICDs in some non-ischemic cardiomyopathy patients, may temper implant volumes, while a limited supply of trained electrophysiologists and implanting physicians constrains access in many regions. In external defibrillation, low public awareness, insufficient CPR and AED training, and the ownership burden of maintenance, batteries, and electrode pads can limit effective use. Together, these cost, safety, regulatory, evidence, and workforce barriers temper the pace of growth, even as the underlying drivers of cardiovascular disease burden, aging, and public-access expansion remain firmly intact.

Defibrillator Market Segment Analysis

The Defibrillator Market is segmented by product type (implantable cardioverter defibrillator [single chamber ICD, dual chamber ICD, CRT-D, subcutaneous ICD (S-ICD)], and external defibrillator [semi-automated, automated, and wearable]), end-user (hospitals, ambulatory surgical centers, homecare settings, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product Type

Dominant Subsegment: Implantable Cardioverter Defibrillator (ICD).

The implantable cardioverter defibrillator segment accounted for 68% of the Defibrillator market in 2025. ICDs are the leading product type because they deliver continuous, long-term protection for patients at high risk of sudden cardiac death, command far higher unit values than external devices, and generate recurring revenue from replacement, leads, programmers, and remote monitoring. Established guideline support for secondary prevention and for selected primary-prevention patients with reduced ejection fraction, together with the expanding use of CRT-D in heart failure, sustains large and dependable implant volumes. Dual chamber ICDs and CRT-D devices anchor value, while subcutaneous ICDs and the new extravascular ICDs are gaining ground among patients who want to avoid transvenous leads, supported by innovation from Boston Scientific, Medtronic, Abbott, and BIOTRONIK. External defibrillators, spanning semi-automated devices, AEDs, and wearable cardioverter defibrillators, are the faster-growing product type, propelled by public-access defibrillation programs, connected AEDs, and wearable adoption. Nonetheless, the high value, recurring nature, and clinical permanence of implantable therapy secure the ICD segment's leadership across the forecast period.

By End-User

Dominant Subsegment: Hospitals.

The hospitals segment accounted for 69% of the Defibrillator market in 2025. Hospitals are the leading end-user because ICD and CRT-D implantation, device programming, lead revision, and follow-up are performed predominantly in hospital electrophysiology and cardiac catheterization laboratories by specialist teams. Hospitals also purchase and maintain the largest fleets of manual, semi-automated, and automated defibrillators for emergency departments, intensive care units, operating rooms, wards, and crash carts, and they are the primary buyers of professional monitor/defibrillators used by emergency medical services. Established reimbursement for inpatient and hospital-outpatient device procedures, along with strong replacement cycles, reinforces the segment's scale. Homecare settings are the fastest-growing end-user, driven by wearable defibrillators, home AEDs, and remote monitoring, while ambulatory surgical centers are gaining share as lower-complexity device procedures shift to outpatient pathways, and the others category captures public-access and emergency-response buyers. Nonetheless, the concentration of implant procedures and equipment purchasing in hospitals secures their clear leadership across the forecast period.

Defibrillator Market Region Analysis

Dominant Region: North America

North America accounted for 45% of the global Defibrillator market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a high burden of cardiovascular disease, widespread ICD and CRT-D implantation supported by established reimbursement, and the presence of leading manufacturers including Medtronic, Boston Scientific, Abbott, Stryker, and ZOLL. The United States has one of the most extensive public-access defibrillation ecosystems in the world, supported by Good Samaritan protections, workplace and school AED programs, and strong emergency medical services networks. Early FDA approvals of novel systems, such as the Aurora extravascular ICD and the Zenix monitor/defibrillator, give patients and clinicians first access to new technology, while high healthcare spending and rapid adoption of connected and remote-monitored devices reinforce demand. Reimbursement strength, regulatory clarity, and a dense network of electrophysiology centers anchor the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Defibrillator market. The region's elevated CAGR is driven by a rising burden of cardiovascular disease, rapidly aging populations, expanding healthcare infrastructure, and growing awareness of sudden cardiac arrest across China, Japan, India, South Korea, and Australia. Japan combines one of the world's oldest populations with long-standing public AED availability and domestic leaders such as Nihon Kohden; China is scaling cardiac-care capacity and local manufacturers such as MicroPort; and India is expanding cardiology access and CPR and AED training. Government healthcare investment, rising procedure volumes, and increasing public-access defibrillation initiatives are accelerating adoption, while global manufacturers expand local presence and regulatory registrations. The combination of high disease burden, infrastructure build-out, and growing device access positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 45% of the global Defibrillator market revenue in 2025. The United States dominates on the strength of its high ICD implantation rates, established reimbursement, extensive public-access defibrillation programs, early access to FDA-approved innovation, and the home bases of leading manufacturers, while Canada and Mexico contribute through expanding cardiac-care and emergency-response networks.

Europe

Europe is a large and advanced regional market, supported by a strong cardiology and electrophysiology base, established CE-marking and EU MDR frameworks, and universal-coverage healthcare systems in Germany, the United Kingdom, France, Italy, and Spain. Home-grown manufacturers such as BIOTRONIK and Philips, together with early CE-market launches such as BIOTRONIK's Acticor Sky and Rivacor Sky and ZOLL's MDR-approved AED 3 and Zenix, reinforce the region's role in both implantable and external defibrillation, while national public-access defibrillation programs continue to widen AED coverage.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a rising burden of cardiovascular disease, rapid population aging, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Japan's mature AED ecosystem and domestic manufacturers, China's expanding cardiac-care infrastructure and local device makers, and India's growing cardiology access and CPR training are accelerating regional adoption and procedure volumes.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding hospital and emergency-care infrastructure, rising cardiovascular disease prevalence, and growing awareness of sudden cardiac arrest are gradually broadening access to both implantable and external defibrillators, while international partnerships, distributor networks, and regulatory harmonization support the build-out of regional capacity.

Defibrillator Market Competitive Landscape

The Defibrillator market is classified as Moderately Concentrated. In implantable defibrillators, a small group of global cardiac rhythm management leaders, including Medtronic, Abbott, and Boston Scientific, anchors the top tier through broad ICD, CRT-D, and subcutaneous portfolios, deep clinical evidence, and large electrophysiology sales forces, with BIOTRONIK and MicroPort challenging through differentiated devices. In external defibrillation, ZOLL, Philips, Stryker, and Nihon Kohden compete across AEDs, professional monitor/defibrillators, and wearable systems through connected-device ecosystems, emergency medical services relationships, and public-access channels, increasing competition in the fastest-growing product segments.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with a few global leaders dominating implantable defibrillators and a more fragmented, multi-vendor field in external defibrillators.
• Leading players: Medtronic, Abbott, and Boston Scientific anchor implantable therapy, while ZOLL, Philips, Stryker, and Nihon Kohden lead external defibrillation.
• Geographic reach: Leaders operate global sales, service, and clinical-support networks; Philips' emergency care business alone serves more than 130 countries with an installed base of more than 3 million AEDs and advanced life support devices.
• Product portfolio strength: Top players offer end-to-end portfolios spanning single chamber, dual chamber, CRT-D, and subcutaneous or extravascular ICDs, as well as AEDs, monitor/defibrillators, and wearable defibrillators.
• Clinical evidence and regulatory track record: Large pivotal trials, long-term registry data, and successful FDA premarket approval and EU MDR certification are decisive advantages in a class III device market.
• Strategic partnerships: Collaborations such as Abbott's January 2026 tie-up with AtaCor Medical on extravascular ICDs and Boston Scientific's modular pairing of the S-ICD with a leadless pacemaker extend technology reach.
• M&A and portfolio activity: Active reshaping, including Philips' agreement to sell its Emergency Care business to Bridgefield Capital and Nihon Kohden's approval to acquire a 90.3% stake in DOWELL Co., Ltd.
• Manufacturing and quality capabilities: High-reliability device manufacturing, battery and high-voltage electronics expertise, and robust post-market surveillance are key competitive moats.
• Innovation focus: Extravascular and leadless-compatible ICDs, conduction-system-pacing-capable devices, connected and cloud-managed AEDs, AI-enabled wearables, and remote monitoring.

Defibrillator Market Recent Developmental Activities

In April 2026, BIOTRONIK, Inc. received U.S. FDA approval for its Acticor Sky and Rivacor Sky ICD and CRT-D systems, which add physiology-driven pacing options, a new anti-tachycardia pacing suite, and workflow features such as automated heart-failure insight and 24/7 MRI readiness. Strategic significance: Brings BIOTRONIK's next-generation high-voltage platform to the U.S., the largest implantable defibrillator market.

In March 2026, Medtronic received FDA approval for an expanded indication of a defibrillation lead for use with conduction system pacing. Strategic significance: Extends Medtronic's defibrillation lead portfolio into physiological pacing approaches and reinforces its leadership in implantable rhythm management.

Defibrillator Market Segmentation

Defibrillator Market by Product Type

• Implantable Cardioverter Defibrillator (ICD)
• Single Chamber ICD
• Dual Chamber ICD
• CRT-D
• Subcutaneous ICD (S-ICD)
• External Defibrillator
• Semi-Automated
• Automated
• Wearable

Defibrillator Market by End-User

• Hospitals
• Ambulatory Surgical Centers
• Homecare Settings
• Others

Defibrillator Market by Geography

• North America Defibrillator Market
• United States Defibrillator Market Size in USD million (2023-2034)
• Canada Defibrillator Market Size in USD million (2023-2034)
• Mexico Defibrillator Market Size in USD million (2023-2034)
• Europe Defibrillator Market
• Germany Defibrillator Market Size in USD million (2023-2034)
• United Kingdom Defibrillator Market Size in USD million (2023-2034)
• France Defibrillator Market Size in USD million (2023-2034)
• Italy Defibrillator Market Size in USD million (2023-2034)
• Spain Defibrillator Market Size in USD million (2023-2034)
• Rest of Europe Defibrillator Market Size in USD million (2023-2034)
• Asia-Pacific Defibrillator Market
• China Defibrillator Market Size in USD million (2023-2034)
• Japan Defibrillator Market Size in USD million (2023-2034)
• India Defibrillator Market Size in USD million (2023-2034)
• Australia Defibrillator Market Size in USD million (2023-2034)
• South Korea Defibrillator Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Defibrillator Market Size in USD million (2023-2034)
• Rest of the World (RoW) Defibrillator Market
• Middle East Defibrillator Market Size in USD million (2023-2034)
• Africa Defibrillator Market Size in USD million (2023-2034)
• South America Defibrillator Market Size in USD million (2023-2034)

Key Takeaways from the Defibrillator Market Report Study

• Market size analysis for the current Defibrillator market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global Defibrillator market.
• Various opportunities available for competitors in the Defibrillator market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current Defibrillator market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for Defibrillator market growth in the future?

Target audience who can benefit from this Defibrillator market report study

• Defibrillator product providers
• Research organizations and consulting companies
• Defibrillator -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in defibrillators
• Various end-users who want to know more about the Defibrillator market and the latest technological developments in the Defibrillator market.

Frequently Asked Questions:

Q1. What is the growth rate of the Defibrillator market?

The Defibrillator market is projected to expand at a CAGR of 7.3% during the forecast period from 2026 to 2034.

Q2. What is the market size of the Defibrillator market?

The Defibrillator market is estimated at USD 13.20 billion in 2025 and is projected to reach USD 24.90 billion by 2034.

Q3. Which region dominates the Defibrillator market?

North America dominated the Defibrillator market with a 45% share of global revenue in 2025, supported by a high cardiovascular disease burden, widespread ICD and CRT-D implantation, established reimbursement, extensive public-access defibrillation programs, and the presence of leading manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Defibrillator market?

The principal drivers are the rising burden of cardiovascular disease and sudden cardiac arrest, with about 19.8 million cardiovascular deaths worldwide in 2022 and more than 350,000 out-of-hospital cardiac arrests annually in the United States; population aging and growth in heart failure; expanding public-access defibrillation and AED adoption; technology innovation in extravascular, subcutaneous, connected, and wearable systems; and a steady cadence of regulatory approvals and product launches.

Q5. Who are the major players in the Defibrillator market?

The major players include Abbott, Medtronic, Boston Scientific Corporation, Stryker, Koninklijke Philips N.V., ZOLL Medical Corporation, MicroPort Scientific Corporation, LivaNova PLC, Biotronik, Inc., and Nihon Kohden Corporation, among other active providers profiled in the Competitive Landscape section. Medtronic, Abbott, and Boston Scientific lead implantable defibrillators, while ZOLL, Philips, Stryker, and Nihon Kohden lead external defibrillation.